M yasthenia gravis (MG) is a T cell-regulated, antibodymediated autoimmune disease. Impaired neuromuscular transmission characteristic of MG results from antibodies against the nicotinic acetylcholine receptor (AChR) of skeletal muscle (1, 2). Nevertheless, a role for T cells in MG and experimental autoimmune MG (EAMG) was shown in several studies (3-7). Previous work performed in our laboratory demonstrated that two peptides representing sequences of the human AChR ␣-subunit, p195-212 and p259-271, were able to stimulate peripheral blood lymphocytes of patients with MG, and to serve as immunodominant T cell epitopes of SJL and BALB͞c mice respectively (8, 9). Altered myasthenogenic peptides, which are single amino acid-substituted analogs of p195-212 (207Ala) and p259-271 (262Lys), as well as a dual altered peptide ligand (APL) composed of the tandemly arranged two single analogs (Lys-262-Ala-207), were synthesized and were shown to inhibit the proliferative responses of both p195-212-and p259-271-specific T cell lines in vitro as well as the in vivo priming to the myasthenogenic peptides (10-12). In addition, the single and the dual APL were also found to be capable of inhibiting the proliferative responses of peripheral blood lymphocytes of MG patients to both myasthenogenic peptides p195-212 and p259-271 (13). The dual APL could reverse myasthenogenic manifestations in mice with EAMG induced either by pathogenic T cell lines or by the Torpedo AChR (10, 14) . In an attempt to elucidate the mechanism͞s by which the dual APL downregulates EAMG-associated responses, we demonstrated that the dual APL acts by actively suppressing myasthenogenic T cell responses in a specific manner. The active suppression is mediated, at least partially, by the up-regulation of the secretion of transforming growth factor (TGF)-␤ [T helper (Th) 3-type cytokine], which was accompanied by down-regulation of IFN-␥ and IL-2 (Th 1-type cytokines) secretion (15). Furthermore, the inhibitory effect of the dual APL could be adoptively transferred to p195-212 or Torpedo AChR-immunized mice (15). Nevertheless, the mechanisms by which the dual APL exerts its effect in vivo have not been completely elucidated yet. Hence, the purpose of this study has been to attempt a better insight into these in vivo mechanisms.
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yasthenia gravis (MG) is a T cell-regulated, antibodymediated autoimmune disease. Impaired neuromuscular transmission characteristic of MG results from antibodies against the nicotinic acetylcholine receptor (AChR) of skeletal muscle (1, 2) . Nevertheless, a role for T cells in MG and experimental autoimmune MG (EAMG) was shown in several studies (3) (4) (5) (6) (7) . Previous work performed in our laboratory demonstrated that two peptides representing sequences of the human AChR ␣-subunit, p195-212 and p259-271, were able to stimulate peripheral blood lymphocytes of patients with MG, and to serve as immunodominant T cell epitopes of SJL and BALB͞c mice respectively (8, 9) . Altered myasthenogenic peptides, which are single amino acid-substituted analogs of p195-212 (207Ala) and p259-271 (262Lys), as well as a dual altered peptide ligand (APL) composed of the tandemly arranged two single analogs (Lys-262-Ala-207), were synthesized and were shown to inhibit the proliferative responses of both p195-212-and p259-271-specific T cell lines in vitro as well as the in vivo priming to the myasthenogenic peptides (10) (11) (12) . In addition, the single and the dual APL were also found to be capable of inhibiting the proliferative responses of peripheral blood lymphocytes of MG patients to both myasthenogenic peptides p195-212 and p259-271 (13) . The dual APL could reverse myasthenogenic manifestations in mice with EAMG induced either by pathogenic T cell lines or by the Torpedo AChR (10, 14) . In an attempt to elucidate the mechanism͞s by which the dual APL downregulates EAMG-associated responses, we demonstrated that the dual APL acts by actively suppressing myasthenogenic T cell responses in a specific manner. The active suppression is mediated, at least partially, by the up-regulation of the secretion of transforming growth factor (TGF)-␤ [T helper (Th) 3-type cytokine], which was accompanied by down-regulation of IFN-␥ and IL-2 (Th 1-type cytokines) secretion (15) . Furthermore, the inhibitory effect of the dual APL could be adoptively transferred to p195-212 or Torpedo AChR-immunized mice (15) . Nevertheless, the mechanisms by which the dual APL exerts its effect in vivo have not been completely elucidated yet. Hence, the purpose of this study has been to attempt a better insight into these in vivo mechanisms.
The term ''regulatory T cell'' describes a variety of T cells that display suppressive functions in vitro or in vivo. One of the best characterized subsets is defined by a constitutive expression of the IL-2 receptor ␣-chain (CD25) (16) . These CD4 ϩ CD25 ϩ regulatory T cells (Treg) play a central role in the maintenance of peripheral tolerance. Depletion of these cells in murine adoptive transfer models leads to various autoimmune diseases (17) . The suppressive function of CD25 ϩ Treg cells and the suppressive capacity depend on direct cell-cell contact. However, once activated, the suppression is antigen nonspecific and independent of inhibitory cytokines (17, 18) .
CD28 and its homologue, cytotoxic T lymphocyte antigen (CTLA)-4, are the primary regulatory molecules that enhance or inhibit T cell activation, respectively. CD4 
Materials and Methods
Mice. Female mice of the inbred strain SJL (The Jackson Laboratory) were used at the age of 8-12 wk.
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Synthetic Peptides and Peptide Analog. Peptide p195-212 (DT-PYLDITYHFVMQRLPL) and the dual APL Lys-262-Ala-207 (VIVKLIPSTSSAVDTPYLDITYHFVAQRLPL), which is composed of the single analogs of p195-212 (Ala-207 in which methionine was substituted by alanine) and of another myasthenogenic peptide p259-271 (VIVELIPSTSSAV) denoted Lys-262 (in which glutamic acid was substituted by arginine), were synthesized and characterized as described (10) . A batch of the dual APL Lys-262-Ala-207 synthesized (97% purity) by UCB-Bioproducts was also used in the present study.
Pretreatment with the Dual APL. SJL mice were injected s.c. with the dual APL (100-500 g per mouse in PBS) or with PBS three times at 2-day intervals. Splenocytes obtained from these mice were cultured in enriched medium for 24 h and 44 h and stained with anti-CD4-phycoerythrin (PE), anti-CD25-FITC Abs and their matched isotype controls. Depletion of CD4 ؉ CD25 ؉ T Cells. The depletion of the CD25 ϩ T cells was performed as follows by using the StemSep system (StemCell Technologies, Vancouver). LN cells obtained from the dual APL-treated mice were incubated with an anti-CD25-biotinylated antibody (clone 7D4; Southern Biotechnology Associates), washed, and incubated with 10% normal mouse serum for 1 h. The cells were further incubated with an anti-biotin tetrameric complex (StemCell Technologies), washed again, and incubated with magnetic beads (StemCell Technologies). The cells were run through a column (StemCell Technologies), and the cell suspension coming out of the column was collected and used for proliferation assay, cytokine secretion assay, and FACS analysis.
Proliferation of LN Cells in the Presence of Anti-CTLA-4-Neutralizing
Antibodies. SJL mice were immunized with 10 g per mouse p195-212 in CFA, and 7 days later part of them were administered s.c. with the dual APL (200 g per mouse in PBS). Ten days after immunization with p195-212, a proliferation assay was performed by using popliteal LN cells obtained from immunized mice (15) 
Results

Treatment with the Dual APL Up-Regulates CD4 ؉ CD25 ؉ T Cells in
Spleens of Treated Mice. We wanted to find out whether the CD4 ϩ CD25 ϩ T cell population has a role in the down-regulating effects of the dual APL. Therefore, SJL mice were pretreated s.c. with the dual APL or PBS. Splenocytes obtained from these mice were cultured in vitro for 24 h and 44 h and stained for CD4 and CD25. After both periods of in vitro culturing, a similar trend was observed, namely, that the s.c. pretreatment with the dual APL increased the size of the CD4 ϩ CD25 ϩ cell population in spleens of SJL mice. The most significant results were obtained after 44 h of in vitro culturing as can be seen in Fig. 1 . It can be seen that the dose of 300 g per mouse dual APL had the most prominent effect on the CD4 ϩ CD25 ϩ T cell population (PBS pretreatment, 4.38%; 300 g per mouse, 7.27%). The dual APL did not affect the CD4 ϩ CD25 ϩ T cell population, when the cells were nonspecifically stimulated in vitro with an anti-CD3 antibody. These representative results repeated themselves in three different experiments.
Administration of the Dual APL to Mice Immunized with p195-212
Increases CD4CD25-Expressing Cells in LN of SJL Mice. We wanted to find out whether the dual APL will also affect the CD4 ϩ CD25 ϩ T cell population when administered concomitant with the myasthenogenic peptide p195-212. To this end, SJL mice were either administered s.c. with the dual APL concomitant with p195-212 immunization, or immunized with the myasthenogenic peptide p195-212 alone. Because most of the in vivo priming inhibition assays were performed 10 days after p195-212 immunization͞dual APL administration, a time point at which the inhibitory effect of the dual APL can be demonstrated very clearly, we followed the kinetics of CD4 ϩ CD25 ϩ T cell population expansion in the LN of the treated mice during this period. (Fig. 4) . Fig. 4 depicts also the effect of the depletion on the secretion of IFN-␥, which is considered to be a pathogenic cytokine in MG. An opposite trend has been observed, namely, LN cells of dual APL-treated mice secreted significantly lower levels of IFN-␥, in comparison We wanted to determine whether the elevation in CTLA-4 expression on LN cells of treated mice observed after dual APL administration is involved in a functional manner in the diminished proliferative response of LN cells of these mice. Because we observed that the elevation in CTLA-4 expression peaks at 72 h after dual APL administration, SJL mice were immunized with the myasthenogenic peptide p195-212 and 7 days later administered s.c. with the dual APL, and their LN cells were harvested 10 days after p195-212 immunization. Fig. 6A shows that administration of the dual APL inhibited the proliferative responses of the LN cells whereas, in the presence of the anti-CTLA-4-neutralizing antibodies, the LN cells regained their capacity to proliferate in response to the priming antigen p195-212 (Fig. 6B) . In contrast, the matched isotype control did not have the same effect on the proliferative responses of the LN cells of the dual APL-treated mice.
Administration of the Dual APL Down-Regulates the Expression of
CD28 on LN Cells of Treated Mice. CD28 and CTLA-4 costimulation molecules were shown to have opposite effects on T cell activation, namely, CD28 being the one that supports T cell activation and CTLA-4 being the molecule that mediates the termination of the immune response. Unlike CTLA-4, which is induced 2-3 days after T cell activation and is not expressed constitutively on the cells, CD28 is expressed constitutively on T cells. Based on that, we wanted to test whether the dual APL has an effect on CD28 expression on LN-derived T cells of treated mice. SJL mice were either administered s.c. with the dual APL concomitant with p195-212 immunization, or immunized with p195-212 alone. LN-derived T cells were obtained from the mice at different time points after p195-212 immunization, and CD28 expression was determined by using FACS analysis. As can be seen in Fig. 7, a significant decrease (p195-212, 66.26% ; p195-212ϩdual APL, 51.52%) was observed 24 h after dual APL administration. A similar effect was also observed 6 (p195-212, 66.34%; p195-212ϩdual APL, 60.18%) and 10 (p195-212, 66.7%; p195-212ϩdual APL, 59.26%) days after dual APL administration, but the differences between the nontreated and the treated mice were less profound. This effect was observed in three independent experiments performed.
Discussion
The results presented in this study show that s.c. administration of the dual APL up-regulated CD4CD25-expressing cells in the spleens and LN of SJL mice. Furthermore, depletion of these cells diminished significantly the inhibitory effect of the dual APL on p195-212-specific proliferative responses and decreased TGF-␤ secretion. The dual APL up-regulated CTLA-4 expression whereas it down-regulated CD28 expression on LN cells. In vitro blockade of CTLA-4 function abrogated the inhibitory effect of the dual APL on the proliferative responses specific to p195-212. Our results suggest that the active suppression exerted by the dual APL is mediated by CD4 ϩ CD25 ϩ cells via upregulation of CTLA-4 expression and TGF-␤ secretion.
The induction of tolerance is essential for the maintenance of immune homeostasis and for the prevention of autoimmune diseases. CD4 ϩ CD25 ϩ T cells have been shown to inhibit autoimmune diabetes in mice and rats (20, 22) , and depletion of these cells in murine adoptive transfer models was shown to lead to various autoimmune diseases (17) . Furthermore, these cells were shown to prevent the expansion of other T cells in vivo (23) and inhibit T cell activation in vitro (24, 25) . It was previously demonstrated by us that the dual APL could inhibit efficiently in vitro and in vivo proliferative responses of myasthenogenicassociated T cell responses (10) . A characteristic feature of CD4 ϩ CD25 ϩ Treg cells in mice and humans is that these cells fail to proliferate and to secrete IL-2 in response to T cell receptor ligation but are able to suppress the responses of both CD4 ϩ and CD8 ϩ T cells (24) (25) (26) . We show in the present study that, on APL administration, the CD4 ϩ CD25 ϩ cells expanded and peaked, in comparison with nontreated mice, at day 5. This first peak is followed by a decrease in the size of this cell population and an additional increase toward day 10. Because the inhibitory effects (inhibition of proliferative responses and an increase in TGF-␤ secretion) of the dual APL were observed at day 10, we suggest that the peak in the size of the CD4 ϩ CD25 ϩ cell population at this day is responsible for the observed suppressive effects. The reason for the decrease in the size of this population observed after day 5 is not clear, but this trend repeated itself in all of the experiments performed.
We have used in the present study the cell depletion technique to confirm the role of CD4 ϩ CD25 ϩ cells in the inhibition of proliferation of LN cells of APL-treated mice. We show here that the depletion of this population of immunoregulatory cells abrogated the suppressive effect exerted by the dual APL on the proliferative responses of the LN cells, namely, these cells play a significant role in the active suppression of the myasthenogenic-associated T cell responses by the dual APL. We have previously demonstrated that the active suppression exerted by the APL is mediated, at least partially, by the up-regulation of the secretion of TGF-␤, which was accompanied by downregulation of IFN-␥ and IL-2 secretion (15) .
It has been reported that cytokines are not essential for the suppression mediated by the CD4 ϩ CD25 (24, 27) . It is noteworthy that we have previously shown that recombinant IL-2 could abrogate the inhibition of LN cell proliferative responses exerted by the dual APL (15) . In contrast to in vitro findings, studies using regulatory T cells in vivo in different settings and different autoimmune models have clearly demonstrated the importance of both IL-10 and TGF-␤ for the function of regulatory T cells. Because we tested the involvement of CD4 ϩ CD25 ϩ cells in an in vivo model, we suggest that in our case there is an important role for cytokines in the mechanism by which these immunoregulatory cells exert their inhibitory effect͞s. Recently, it was proposed by Jonuleit et al. (28) that the CD4 ϩ CD25 ϩ T cells may not represent the regulatory T cell population per se, but rather a population that is required for the differentiation and expansion of bona fide regulatory T cells that release inhibitory mediators such as biologically active TGF-␤. This secondary systemic suppressive effect mediated by induced suppressor cells is cell contact independent (28) . We show here that CD4 ϩ CD25 ϩ cell depletion resulted in a decrease in TGF-␤ secretion, accompanied by an elevation in IFN-␥ secretion. The effect of the depletion on TGF-␤ secretion was observed in most of the experiments, but not in all of them. It is possible that, in those cases where we could not observe the effect of the dual APL on TGF-␤ secretion, the relatively high number of immunoregulatory cells, induced by the dual APL, exerted their inhibitory effect through cell-to-cell contact and not through TGF-␤ secretion. On the other hand, in the experiments in which up-regulated secretion of TGF-␤ was observed, the number of immunoregulatory cells was lower, and a secondary systemic effect mediated by induced suppressor cells secreting TGF-␤ was required for an efficient inhibitory effect of the APL. It thus seems that TGF-␤ is involved in the inhibitory effect of the dual APL, but in certain circumstances this effect can be mediated without the presence of this cytokine.
To further elucidate the mechanism͞s by which the dual APL suppresses myasthenogenic-associated T cell responses, we tested whether it has an effect on the expression of the costimulation molecules CD28 and CTLA-4. We show here that dual APL administration down-regulated CD28 expression on LNderived T cells while up-regulating CTLA-4 expression. Furthermore, anti-CTLA-4-neutralizing antibodies abrogated the inhibitory effect of the dual APL on the LN cells' proliferative responses. It is noteworthy that the dual APL did not have the same effect on CTLA-4 expression when the mice were immunized with ovalbumin and administered s.c. with the dual APL (data not shown). Based on these results, it seems that, in this specific early stage of activation of the T cells, the dual APL increases CTLA-4 expression on a very small population of cells, namely cells that encountered p195-212, and has no effect on cells primed with another antigen.
It is currently thought that CD28 provides naive T cells with a costimulatory signal for promoting IL-2 formation and cell expansion as well as preventing induction of anergy and cell death. On the other hand, CTLA-4 that is expressed on T cell activation, apparently transduces a negative signal to activated T cells, thereby attenuating the T cell responses (29) (30) (31) . Furthermore, it was previously demonstrated that CTLA-4 expression is up-regulated after T cell activation and reaches a maximum after 2-3 days (32), a range of time that correlates with the peak in CTLA-4 expression observed by us, on dual APL administration.
It was previously demonstrated that a costimulatory signal through CTLA-4 is required for the activation of CD4 ϩ CD25 ϩ Treg cells to mediate suppression (19) (20) (21) . However, the upregulation in CTLA-4 expression observed by us does not exclude the possibility that CTLA-4 is not the only accessory molecule required for the activation of the CD4 ϩ CD25 ϩ cells. In contrast to CTLA-4, the CD4 ϩ CD25 ϩ Treg cells apparently do not need CD28 for their activation (21, 24, 27) . We cannot be certain that the changes in CD28͞CTLA-4 expression on the dual APL administration occurred only on CD4 ϩ CD25 ϩ cells. Nevertheless, the results mentioned above regarding these costimulatory molecules suggest that the dual APL induces the suppressive activity of the immunoregulatory cells by upregulating the expression of the inhibitory costimulatory molecule (CTLA-4) while decreasing the expression of the activating costimulatory molecule (CD28). Alternatively, it is possible that the up-regulation of CTLA-4 expression occurred on CD4 ϩ CD25 ϩ cells and the down-regulation of CD28 occurred on the pathogenic T cells. The up-regulation of CTLA-4 expression is in agreement with the up-regulation of TGF-␤ secretion observed on the administration of the dual APL. It has been reported that cross-linking of CTLA-4 may enhance production of TGF-␤ by activated T cells (33, 34) . This finding raises the possibility that CTLA-4 does not directly inhibit T cell activation but does so by the active induction of this inhibitory cytokine.
Most of the reports on CD4 ϩ CD25 
